To claim credit and obtain further information, including faculty disclosures, visit i3Health.com/ODA-cervical.

While the survival rate for localized cervical cancer is high, patients with metastatic disease face a poor prognosis with limited treatment options. This episode of Oncology Data Advisor will provide an update on immunotherapeutic strategies for recurrent and metastatic cervical cancer. It features perspectives from two noted experts in the field: Dr. Bradley Monk, Professor of Gynecologic Oncology at the University of Arizona College of Medicine; and Ms. Jennifer Filipi, nurse practitioner at Massachusetts General Hospital.

This activity is supported by an independent educational grant from Merck. Free CME and NCPD credit are available for this podcast.